Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the abstract featuring previously announced preclinical data demonstrating positive results for PXL065, the deuterium-stabilized R-enantiomer of pioglitazone, in hypertrophic cardiomyopathy 1, has been accepted for presentation at the 2025 edition of the European Society of Cardiology (ESC) Congress (link), to be held jointly with World Congress of Cardiology, on September 1 st, 2025 at 11:15 am CEST, in Madrid, Spain.
Prof. Dr. Cordula Wolf, Director of the Center for Rare Congenital Heart Diseases at the TUM University Hospital German Heart Center, stated: 'The compelling results obtained in this study illustrate the potential of PXL065 in HCM, the most common genetic cardiac disorder. Current treatments have important limitations in efficacy, safety, or patient applicability. There is a clear unmet need for safe and effective disease-modifying therapies.'
Thomas Kuhn, CEO of Poxel, added: 'We are pleased to have the data with PXL065 in HCM be presented at one of the world's leading forums for cardiovascular science and medicine, which underscores both the quality and relevance of these findings. We look forward to further supporting PXL065 development for the treatment of HCM based on these promising results.'
Hypertrophic Cardiomyopathy (HCM) is a genetic disorder marked by myocardial hypertrophy, cardiac fibrosis, ventricular dysfunction, arrhythmias, and an increased risk of sudden cardiac death. It is caused by mutations in sarcomere protein genes, leading to altered cell metabolism, including oxidative stress and mitochondrial dysfunction. The estimated prevalence of HCM is 0.2%, or 1/500 adults, and its incidence is around 5 per 100,000 person-years.
In connection with the mechanism of action of PXL065 on the inhibition of the mitochondrial pyruvate carrier (MPC) and on the inhibition of Acyl CoA Synthetase 4 (ACSL4) thus acting on oxidative stress, inflammation and fibrosis, PXL065 was successfully assessed in an established mouse model of hypertrophic cardiomyopathy.
This preclinical study was funded by the German Center for Cardiovascular Research (DZHK) and conducted at the TUM University Hospital German Heart Center by leading HCM expert Prof. Dr. Cordula Wolf. Poxel and the TUM University Hospital German Heart Center collaborated on the pre-clinical study based on Poxel's existing data and patent portfolio on PXL065 and prior research conducted by Prof. Dr. Cordula Wolf and her group on the disease mechanisms and therapeutic use of TZD's in HCM.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
1
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
21 hours ago
- Washington Post
Ex-Texas US Rep. Blake Farenthold, who left office amid harassment allegations, dies at 63
Former Texas Republican U.S. Rep. Blake Farenthold , who left Congress amid sexual harassment allegations, has died. He was 63. He died in a Corpus Christi hospital and suffered heart and liver problems in recent years, Steve Ray, his former longtime political consultant, said. Farenthold's wife, Debbie Farenthold, confirmed that he died Friday.
The Hill
a day ago
- The Hill
Delaware governor signs executive order protecting gender-affirming care
On Friday, Delaware Democratic Gov. Matt Meyer signed an executive order increasing protection for receivers and providers of gender-affirming care. 'In Delaware, we cherish privacy, dignity and the right to make personal medical decisions. Everyone deserves the freedom to access healthcare rooted in science and compassion,' said Meyer. The executive order prohibits any state agency from providing 'medical records, data or billing information, or utilize state resources' that could help any criminal or civil investigation against someone receiving or providing gender-affirming care. It also dictated that the state professional regulations board cannot disbar healthcare professionals only due to providing gender-affirming care. California, New York, Illinois and 11 other states, and Washington, D.C., have enacted similar legislation to shield patients and doctors from aggressive legislation in states where gender-affirming care is highly restricted. Patients can now travel to shield states to receive their care without fear of retribution in their home states. This comes after a Supreme Court decision on June 18 that upheld Tennessee's decision to ban puberty blockers and hormone treatments for transgender minors. 'This ruling undermines doctors in delivering care to some of the most vulnerable patients in our country,' Rep. Sarah McBride (D-Del.), the nation's first openly transgender member of Congress, said Wednesday on the social platform X. Since President Trump took office transgender rights have increasingly been limited. Trump signed an executive order recognizing only two genders, has tried to ban transgender troops from the military, has refused requests to change the gender of passports and has tried to defund gender-affirming medical care. Delaware has a long history of tolerance for LGBTQ populations. According to the order, the state hosts 40,000 LGBTQ individuals and 6,300 transgender adults. In 2013, it legalized same sex marriage and implemented anti-discrimination laws in housing, employment and public accommodation. 'We will do everything in our power to protect transgender families in the state of Delaware and throughout the country,' the Executive Committee of the Delaware Democratic Party PRIDE Caucus said in a press statement earlier this week. 'We call on every legislator, from the state and county level to the federal level, to speak out and step up. This is the moment to act – not with caution, but with courage.'
Yahoo
a day ago
- Yahoo
Health care has been a job market bright spot, but Trump's budget bill looms over the industry
Proposed cuts to health insurance programs in the budget bill being pushed through Congress by President Donald Trump could put hundreds of thousands of health care jobs at risk — jeopardizing one of the few notably strong areas of the U.S. job market. Congressional Republicans are advancing a budget plan that would cause nearly 8 million people on Medicaid to lose their health insurance coverage, according to estimates by the Congressional Budget Office, with an additional 2 million people to lose coverage through the Affordable Care Act if Congress remains on track to let health insurance tax subsidies expire at the end of the year. Less funding for Medicaid and fewer people with health insurance would mean a drop-off in doctor's office visits, prescription refills and medical procedures — and, as a result, fewer workers needed to support those types of services. It could lead to the loss of nearly 500,000 health care jobs over the next decade, according to an analysis by George Washington University and the Commonwealth Fund. The expiration of the ACA tax subsidies, which were enacted in 2021, would result in the loss of an additional 140,000 jobs, a separate analysis from George Washington University found. 'Hospitals will close, health centers will close, pharmacies in some parts of the country will close because they will lose revenue,' said Leighton Ku, director for the Center for Health Policy Research at George Washington University, who worked on the analyses. 'There are going to be job losses, and we're talking about middle class jobs being lost.' That would be a blow to one of the strongest, steadiest areas of the job market in recent years. Health care accounted for nearly half of the jobs added in the U.S. in May, according to the Bureau of Labor Statistics. Last year, around half of the 2.2 million jobs added to the economy were in health care-related sectors, according to an analysis by S&P Global. That has helped offset job cuts and stagnant growth in other sectors of the labor market, like retail and manufacturing. 'Right now, a lot of what is driving these positive headline numbers and bolstering the labor market is the health care sector,' said Allison Shrivastava, an economist with job listing site 'It's something that has been a constant. The health care sector has been a pretty big mainstay as the rest of the labor market has cooled.' The health insurance provisions are part of a broader spending bill that has passed the House and is currently making its way through the Senate. The legislation, which Republicans have dubbed the "Big Beautiful Bill Act," would cut around $800 billion from Medicaid, the health insurance program for the poor and disabled, in order to help offset some of the $4 trillion in tax cut extensions in the bill for individuals and corporations. A version of the bill currently in the Senate, which plans to start voting on the legislation next week, would go even further in reducing spending on Medicaid, by including a provision to limit states' use of taxes on hospitals and other health care providers that help states fund their share of the Medicaid program. The cuts would take a particular toll on health care providers in rural areas, where patients are more likely to be insured through Medicaid than those in metro areas. Researchers at Georgetown University found that 40% of children in small and rural towns receive their health insurance from Medicaid. Already, one-third of all rural hospitals in the country are at risk of closing because of financial difficulties, according to a report this month from the Center for Healthcare Quality and Payment Reform. Also at risk are Community Health Centers, which employ more than 300,000 workers and receive a portion of their funding from the federal government. Those centers, which serve at least 32 million mostly lower-income patients a year, get about 40% of their revenue from Medicaid. 'Our health centers operate on razor-thin margins, so any kind of disruption in payments or reimbursements, even for a short time, can have a significant impact,' said Joe Dunn, chief policy officer for the National Association of Community Health Centers. 'About 40% of health centers are in rural America, and oftentimes they are the only primary care in that community. We have health centers in towns of a few hundred people, and there may not be any other kind of health care network there.' Absent any policy changes from Congress, the health care sector had appeared to be on track for continued growth — and largely isolated from wider concerns about tariffs and an economic slowdown. The number of job postings for doctors and surgeons on are about 90% higher than their pre-pandemic levels, listings for home health aides are up 46%, and openings for nurses are up 16%, Shrivastava said. Health care job postings on represent 27% of all active job listings and health care postings are beginning to make up a larger share of new job postings, according to data from ZipRecruiter. A loss of that hiring momentum from funding cuts would leave one less positive driver for the job market. 'Right now, the labor market as a whole is arguably in a stagnant position,' said Shrivastava. 'People are not wanting to leave their jobs, they're nervous about whether or not they'll be able to find another job, and companies aren't really looking to hire. Health care has been the exception to that.' This article was originally published on
